A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis

Abstract

Objectives:

This study is aimed at providing a quantitative evaluation on different therapies of spasticity caused by multiple sclerosis.

Data sources:

PubMed and Embase database.

Review methods:

We searched for randomized controlled trials that met the requirements. Percentages of improved patients’ spasticity scale, mild adverse effect and severe adverse effect were extracted as outcomes. The forest plots accompanied with surface under the cumulative ranking curves were used to reveal the efficacy and safety of these therapies.

Results:

In all, 23 randomized controlled trials with a total of 2720 patients were included in our study. Cannabinoids and botulinum toxin had shown a significantly better efficacy than placebo in the percentage of improved patients. Botulinum toxin also showed such significant difference compared with tizanidine and baclofen. No significant difference was found in spasticity scale. Cannabinoids, tizanidine and diazepam had significantly more mild adverse effect reports than placebo. Surface under the cumulative ranking curves suggested that cannabinoids, botulinum toxin and transcutaneous electric nerve stimulation were preferable therapies.

Conclusions:

We recommended botulinum toxin as the optimal intervention for multiple sclerosis–related spasticity. Cannabinoids and transcutaneous electric nerve stimulation could also be considered as multiple sclerosis–related spasticity treatments but their safety remained to be verified.

Keywords

Spasticity multiple sclerosis efficacy safety network meta-analysis

Get full access to this article

View all access options for this article.

References

Amatya

Khan

La Mantia

et al . Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev 2013; 2: CD009974.

Iodice

Dubbioso

Ruggiero

et al . Anodal transcranial direct current stimulation of motor cortex does not ameliorate spasticity in multiple sclerosis. Restor Neurol Neurosci 2015; 33: 487–492.

Novotna

Mares

Ratcliffe

et al . A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18: 1122–1131.

Shaygannejad

Janghorbani

Vaezi

et al . Comparison of the effect of baclofen and transcutaneous electrical nerve stimulation for the treatment of spasticity in multiple sclerosis. Neurol Res 2013; 35: 636–641.

Eyssette

Rohmer

Serratrice

et al . Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988; 10: 699–708.

Whiting

Wolff

Deshpande

et al . Cannabinoids for medical use: a systematic review and meta-analysis. J Am Med Assoc 2015; 313: 2456–2473.

Zajicek

Hobart

Slade

et al . Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012; 83: 1125–1132.

Wade

Collin

Stott

et al . Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010; 16: 707–714.

Ansari

Naghdi

Arab

et al . The interrater and intrarater reliability of the Modified Ashworth Scale in the assessment of muscle spasticity: limb and muscle group effect. Neurorehabilitation 2008; 23: 231.

10.

Hyman

Barnes

Bhakta

et al . Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707–712.

11.

Zajicek

Fox

Sanders

et al . Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517–1526.

12.

Wade

Makela

Robson

et al . Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434–441.

13.

From

Heltberg

. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand 1975; 51: 158–166.

14.

Collin

Ehler

Waberzinek

et al . A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32: 451–459.

15.

Leocani

Nuara

Houdayer

et al . Effect of THC-CBD oromucosal spray (Sativex) on measures of spasticity in multiple sclerosis: a double-blind, placebo-controlled, crossover study. Mult Scler 2014; 20: 498–500.

16.

Vaney

Heinzel-Gutenbrunner

Jobin

et al . Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417–424.

17.

Brar

Smith

Nelson

et al . Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil 1991; 72: 186–189.

18.

Basmajian

Shankardass

Russell

. Ketazolam once daily for spasticity: double-blind cross-over study. Arch Phys Med Rehabil 1986; 67: 556–557.

19.

Tolosa

Soll

Loewenson

. Letter: treatment of spasticity in multiple sclerosis with dantrolene. J Am Med Assoc 1975; 233: 1046.

20.

Collin

Davies

Mutiboko

et al . Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290–296.

21.

Killestein

Hoogervorst

ELJ

Reif

et al . Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404–1407.

22.

Corey-Bloom

Wolfson

Gamst

et al . Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 2012; 184: 1143–1150.

23.

Smith

Birnbaum

Carter

et al . Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology 1994; 44: S34–42; discussion S42–S43.

24.

Hoogstraten

Van Der Ploeg

RJ and

Vd Burg

et al . Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand 1988; 77: 224–230.

25.

Bass

Weinshenker

Rice

GPA

et al . Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988; 15: 15–19.

26.

Stien

Nordal

Oftedal

et al . The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75: 190–194.

27.

Snow

Tsui

JKC

Bhatt

et al . Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 1990; 28: 512–515.

28.

Dressler

Bhidayasiri

Bohlega

et al . Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-interdisciplinary working group for movement disorders task force. J Neurol 2017; 264: 112–120.

29.

Miller

Mattison

Paul

et al . The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 2007; 13: 527–533.

30.

Paisley

Beard

Hunn

et al . Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler 2002; 8: 319–329.

31.

Shakespeare

Boggild

Young

. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003; 4: CD001332.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.47 MB

0.34 MB